{"name":"Esperion Therapeutics, Inc.","slug":"esperion-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ETC-1002","genericName":"ETC-1002","slug":"etc-1002","indication":"Hypercholesterolemia and dyslipidemia (as monotherapy or in combination with statins)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ezetimibe 10mg","genericName":"Ezetimibe 10mg","slug":"ezetimibe-10mg","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"ETC-1002","genericName":"ETC-1002","slug":"etc-1002","phase":"phase_3","mechanism":"ETC-1002 activates AMP-activated protein kinase (AMPK) to reduce cholesterol synthesis and increase cholesterol catabolism, thereby lowering LDL cholesterol levels.","indications":["Hypercholesterolemia and dyslipidemia (as monotherapy or in combination with statins)","Cardiovascular risk reduction in patients with elevated LDL cholesterol"],"catalyst":""},{"name":"Ezetimibe 10mg","genericName":"Ezetimibe 10mg","slug":"ezetimibe-10mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPUnhKTXQ4S2tzbk03c3pDUkdYbVRLMXBObGFSc3ZvQThVX2tUTVo2cDRJd29LUTVuS3FieVNnRnVLakxGUDNPT25tUnFKMWRjU21Ecjh1UXAwSFYtVTdjelVPcDN4bXk5WjdwdkpDOVN6eU9IcGItNTRpMTZWRnZPREpHYlRYRTFZYklBclR4SWtTSHJfTlFseElYLTlna0FwSnBSeVpCbUNMeU41MFBrdTQ0aUt5eFlvNmlyeVI1Q2UyUQ?oc=5","date":"2026-03-04","type":"deal","source":"TradingView","summary":"ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView","headline":"ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNYzdHZUF4QmhKRHlIRGlTMXZ5cGU5ZUtTUHBoNU9TcDJ1WXJOb1kyQy1zOTgtUjRIWkJiUV9ESDQxYkdLcUhiejVXTmdCTV9hN1A2cmlIcF9GZW14WFlzNlozb3VNZ0xyMzUxN1Jrbk5aRmV4a1VpV25xMHQ4WVduVjc3ZUNWY054VXdkNnhIWF9XNkNfMkEw?oc=5","date":"2026-03-04","type":"deal","source":"Pharmaceutical Technology","summary":"Esperion to acquire Corstasis for cardiovascular franchise expansion - Pharmaceutical Technology","headline":"Esperion to acquire Corstasis for cardiovascular franchise expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNSjFQVUEydWFybmtOY3haUE81aklEcy15ZTdHMjBDcHN6NDg3VXhJQ3hSeEw4a0FubmpJbUZieGZZM0ZEdnpsREMtdjU4UjRfWmJZRmU2TVZYdGZIYWl6T0RzSzM1ZUtIZ3hqU0FpYnpiMmdNejdkSE5iMWFuU1RXYlFfM1R2ZE1XRGNTZ2NSQQ?oc=5","date":"2026-03-03","type":"deal","source":"The Pharma Letter","summary":"Esperion to acquire Corstasis Therapeutics - The Pharma Letter","headline":"Esperion to acquire Corstasis Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPcEJtbGtGNGU5U2liOWx3SjQ2WS1lalRhanRrQzVEME5RT2JnQTlzdTliYzhiNlk4S0tCbnJlNzI5WVh5MzJ4bHBaZU5WU3l1SjF3YTh6aUhZOFVKdXZjYjdFRExyTGlPdk15dDRVQ2lWZTl6dzVsQlcxOHotWGM2Rm5OYUFfQ0RkVnVmYWZjblBUR2M0MTRYQ0FCVllRbkcxU2l3?oc=5","date":"2026-03-03","type":"regulatory","source":"Fierce Pharma","summary":"Esperion pays $75M-plus to acquire Corstasis and newly approved Enbumyst - Fierce Pharma","headline":"Esperion pays $75M-plus to acquire Corstasis and newly approved Enbumyst","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPWE5PeDl6VGpTS2dfMDZUcVk1STN4LUhpdkJwS19NX0RCamlac2NzbGw5N3hkdTg1Q2xUd1VHLWZTQjdpLXlIdXhycFIycnMwSWxxRXlVcDNMblQtTEVnRjlSXzdvNHVzUThNN3VBMExMRnB0QmlhUmRWSXh0Y1RiZnhka3ZNTmtHekcydVJoSXNGS3EzM2RBNExyRVhuMTh0SzdFc1JGdzBKRVNTNVRnamlTQkYxQXlQOTczUzl3aEZ2WDZ1WUJfZllBb0diSWZmMDJBUFpsdzNIak9UcWRNREYzdll2SjJWT2ZORFBxQkdSWk1tRGww?oc=5","date":"2026-03-03","type":"deal","source":"Citeline News & Insights","summary":"Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights","headline":"Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNYVYyUTFLa1BYMW14T1VGUGxTOGdWekpRaU9CdV9tT202TnFmalVVdXE2V2cwYWkwZlhRUFpNNVV3NjdVSjBlSFlwcEpleUtTUUJQNENQTlAxY1d2SnpDbW1LbDIzMUhXd0xDckJYRnNFOUZWR041TnpYQ0NENTBvZ29WaTBRSXZyaXMweExIMjRaY3hyRkJ1WENuOFExYVRmNFBsWXBjdTY3N0g5N1V0ckREZkhHOEo1Y3BwWXJ1V3RxTHNvRjJqSnk1NC1oV2QwR0s0QWw2cw?oc=5","date":"2026-02-18","type":"patent","source":"Cardiovascular Business","summary":"Esperion settles another lawsuit to keep generic versions of popular drug off shelves - Cardiovascular Business","headline":"Esperion settles another lawsuit to keep generic versions of popular drug off shelves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gJBVV95cUxQcVRWdE9OVEF2TjAzcVBSVlp5WnFZbEFzS1JBNnJqMVdhMGhuU05ZMkdueEFIOWw3bVNqVDZfZXRwenlSd0FrWmZjQ1prT3d2RHhSYmJJazJCMkNmVmQ2MVhKSXhMZE13NXNlTEZqb0EtNXpDVEpWT0ZDVkRmb3ViM3hSUDdQcWJvNjJpWXlfME9fSzk3VXFUVERSbTktQ3ZKRW04czhoSTVLMGRBZFRNb1Y3NFBsVllZVndRSHhsbmxwY0x0QW56bThrOGF5czlPbmZ1cUdEeVNodWtLemxPNzFJb01WMDMwNGRaWWNsZnNjb3g5cnNYR3djT25Jem42QloyQ2JSUW05MjNZMWVRM1RKTkxzVFpxa2xESTc2ang3S3p3akRsY1NsUENWdWNUZDhZNGpEbTRQUGJlaDdPdm8wcUVXd2RDZWZHVk9TMkxQcVNLWVJBUWRtY3VIMTRyUk1HMUxR0gHrAkFVX3lxTE1LRG1FTE9MVEpVZVVONVFNUExudGtXclFBZFVmVjIwN2tJOEtpVkdYQy0wc3RwN2FlcUR3OTVVMjczdHFVWTZacmwtTU9RUGNDM1NhVEZZZFpudS1nRDhxYWdzMG9xSVRyU1AtVUJpTXZSMktQSGxJbzJDdHg5Vk9JX3FoSzRkVHdrS0lqZFBheHFWOTRFLU1HY3dKWllGWUg1UXFla0w2VjJwSDNyR0FCVFU5Tm5iLUVmVGJhcE9iU0pEQVRId3RWdUVsZG1abF9OSzlVMkVrTkZzaDZKU2g1SDN0OUZodGxfQnBkY3hHdTFmOFM4TG9xZnNLWWgxOUd4TGI5SW40QU5DZXdfT2Z0MGlpeXJiOHlfRGsybEttb3BOTklFYWYyeTQxSE5nbzhfVHVubDIzT29KUmQyTVlVdXppMHhtWFZJOEt2TlNmcUlVQnNoQVJJWThZRTFEd2dHbjFJMWZkcTc5TQ?oc=5","date":"2026-02-17","type":"patent","source":"The Manila Times","summary":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 - The Manila Ti","headline":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOZldualVTcmR3dTVxZFhWSnVwdXZfbjl2d2MzWklGYW5GWXJON3hWNVdINzNaVFllZHdjd3QyM1JyRTVnVEZ1NVNtMDRrcndsQ01TLWtnU1pkVXU0bjdJdjNOQU5tUlhfSmdxbmg0MXc1aHVlZ2Rsc1NtVGkxbTFEUzlvVE9XRDFscjJlN19jU2JNM0tzVnZxelNIdEVoUjFCUUhzdFdn?oc=5","date":"2026-01-12","type":"earnings","source":"BioWorld News","summary":"JPM 2026: Year kicks off with biopharma Q4 revenue and guidance - BioWorld News","headline":"JPM 2026: Year kicks off with biopharma Q4 revenue and guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQVpGN25rQkUtdUhhbHhjSTJXc0hBV1FfNHRVQkNwTXU2WFdKelQ3a3ctMVlsWl94MmFlbllWWUpYdHBmdDFHdEZ3NndmZG0zZ1VDak1YMVdjS0Q4bFBJMHFkc2pabTFrWVRub083Nk5UaTlxb1dxQVRKSXNXWk9MU0VqNGV2R2RGakJLQUUtdXNmZGpNTTJIdlp3RThPS3BFU2V1emVnVmlSWm1ZenhUOGoyMnkxNEloLXpQd2diTQ?oc=5","date":"2025-10-06","type":"patent","source":"TradingView","summary":"ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up - TradingView","headline":"ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUFM4bGJnZnFiM1RfMTJXbGRYdnlrdHFlWUFnSFFoZUp0dlRJU1JERjVJbl8takFCUmlZMk1xekh3MU9GMkVMekk4c1RJMlFfY3dTbGRuWHhweXVjNllDbi1FRFJnbkp5dUNFdXRFdVBWbUp2UG9tS20yLUIxbTc4Y3M0Yk9XaHFsN2tKTnR4bGE0SmZNMENqcHJUa1pyWGxjZWg0V1V5dkppblRwZjJBelFFVEFmdm5ocmdJ?oc=5","date":"2025-10-03","type":"patent","source":"Stock Titan","summary":"Generics Blocked Until Apr 19, 2040 — Esperion Reaches Settlement with Dr. Reddy's on NEXLETOL/NEXLIZET - Stock Titan","headline":"Generics Blocked Until Apr 19, 2040 — Esperion Reaches Settlement with Dr. Reddy's on NEXLETOL/NEXLIZET","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQbHVjSmpDYzNHVDFlZmdNcWN3YmM3UnZhVVhFdmRvb3dqYklyUGpVVE1BUUQ5ZWFpMk9vSEdBRUthT3JEVHNMeFVMZ2VxZlp1YUxZYVNxSnFwSmhDX0RZUWFhczhTeWx6ZG5CczNkOGktazZmeTZ2aURULXpJc3JyWUFhdXB1WXBDd080b2k2LTBOUQ?oc=5","date":"2025-10-03","type":"patent","source":"finance.yahoo.com","summary":"Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to Apri","headline":"Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOZGEwY1JTRmd3RjZnX3dmT094NzhNNXk4Mm1CN0hCTGc0ME0xYnppSWNOdzBMYV9TTTlSMEFma3lZZ3BaN3E5NnBjbTZGUlJFM2RZc2E2bkdBNnVpTURCN2NXT1RKbjk1REdwU0JxZWdBVTlSRmlwT0t1MUpwX2F1bGZ1cUp1WmRrUEln?oc=5","date":"2025-07-29","type":"pipeline","source":"finance.yahoo.com","summary":"Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors - finance.yahoo.com","headline":"Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}